- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03460977
PF-06821497 Trattamento di SCLC recidivante/refrattario, carcinoma prostatico resistente alla castrazione e linfoma follicolare
UNO STUDIO DI COORTE DI FASE I DOSE ESCALATION E AMPLIATO DI PF-06821497 NEL TRATTAMENTO DI PAZIENTI ADULTI AFFETTI DA CANCRO POLMONARE A PICCOLE CELLULE (SCLC) RECIDIVATO/REFRATTARIO, CARCINOMA PROSTATICO RESISTENTE ALLA CASTRAZIONE (CRPC) E LINFOMA FOLLICOLARE (FL)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Pfizer CT.gov Call Center
- Numero di telefono: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Luoghi di studio
-
-
-
Haskovo, Bulgaria, 6300
- Terminato
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510120
- Attivo, non reclutante
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, Cina, 410013
- Attivo, non reclutante
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210009
- Attivo, non reclutante
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, Cina, 210008
- Attivo, non reclutante
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- Reclutamento
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, Cina, 325000
- Attivo, non reclutante
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Corea del Sud, 13620
- Reclutamento
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Corea del Sud, 03080
- Attivo, non reclutante
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Corea del Sud, 07985
- Attivo, non reclutante
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Corea del Sud, 03722
- Attivo, non reclutante
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Corea del Sud, 35015
- Attivo, non reclutante
- Chungnam national university hospital
-
-
-
-
Chiba
-
Kashiwa, Chiba, Giappone, 277-8577
- Attivo, non reclutante
- National Cancer Center Hospital East
-
-
-
-
-
Bydgoszcz, Polonia, 85-048
- Non ancora reclutamento
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Polonia, 75-581
- Attivo, non reclutante
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Polonia, 30-348
- Reclutamento
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Polonia, 35-326
- Attivo, non reclutante
- Centrum Medyczne MEDYK
-
Warsaw, Polonia, 02-781
- Attivo, non reclutante
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow, Russia, 117186
- Attivo, non reclutante
- LLC "Neyro-klinika"
-
Moscow, Russia, 125284
- Terminato
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Russia, 129301
- Terminato
- SBHI of Moscow City Clinical Hospital
-
Omsk, Russia, 644013
- Terminato
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Russia, 197341
- Terminato
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Russia, 197758
- Terminato
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Russia, 198255
- Terminato
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Russia, 150054
- Terminato
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Russia, 196603
- Attivo, non reclutante
- Private Medical Institution "Euromedservice"
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spagna, 08036
- Reclutamento
- Hospital Clinic de Barcelona
-
Barcelona, Spagna, 08023
- Reclutamento
- Hospital Quironsalud Barcelona
-
Madrid, Spagna, 28034
- Reclutamento
- Hospital Universitario Ramon y Cajal
-
Madrid, Spagna, 28040
- Reclutamento
- Hospital Clinico San Carlos
-
Madrid, Spagna, 28050
- Reclutamento
- Hospital Universitario HM Sanchinarro
-
Madrid, Spagna, 28040
- Reclutamento
- H.U. Fundación Jiménez Díaz
-
Madrid, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 De Octubre
-
Málaga, Spagna, 29010
- Reclutamento
- Hospital Universitario Virgen de la Victoria
-
Valencia, Spagna, 46026
- Attivo, non reclutante
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, Spagna, 08908
- Attivo, non reclutante
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, Spagna, 12002
- Attivo, non reclutante
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spagna, 28223
- Reclutamento
- Hospital Quironsalud Madrid
-
-
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- Attivo, non reclutante
- Banner-University Medical Center Tucson
-
Tucson, Arizona, Stati Uniti, 85719
- Attivo, non reclutante
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, Stati Uniti, 85724
- Attivo, non reclutante
- The University of Arizona Cancer Center
-
Tucson, Arizona, Stati Uniti, 85741
- Terminato
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, Stati Uniti, 92801
- Attivo, non reclutante
- Pacific Cancer Medical Center INC
-
Duarte, California, Stati Uniti, 91010
- Attivo, non reclutante
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Stati Uniti, 91010
- Attivo, non reclutante
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, Stati Uniti, 06856
- Attivo, non reclutante
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, Stati Uniti, 66205
- Attivo, non reclutante
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, Stati Uniti, 66205
- Attivo, non reclutante
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, Stati Uniti, 66160
- Attivo, non reclutante
- The University of Kansas Hospital
-
Kansas City, Kansas, Stati Uniti, 66160
- Attivo, non reclutante
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, Stati Uniti, 66211
- Attivo, non reclutante
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, Stati Uniti, 66205
- Attivo, non reclutante
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40202
- Attivo, non reclutante
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, Stati Uniti, 40202
- Attivo, non reclutante
- Norton Hospital
-
Louisville, Kentucky, Stati Uniti, 40202
- Attivo, non reclutante
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- Terminato
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Attivo, non reclutante
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stati Uniti, 02115
- Attivo, non reclutante
- Brigham and Women's Hospital
-
Newton, Massachusetts, Stati Uniti, 02459
- Attivo, non reclutante
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68130
- Reclutamento
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Attivo, non reclutante
- Hackensack University Medical Center
-
Hackensack, New Jersey, Stati Uniti, 07601
- Attivo, non reclutante
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Reclutamento
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Reclutamento
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Terminato
- Texas Oncology - Austin Midtown
-
Dallas, Texas, Stati Uniti, 75390
- Attivo, non reclutante
- UT Southwestern Medical Center
-
Dallas, Texas, Stati Uniti, 75390
- Attivo, non reclutante
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, Stati Uniti, 75390
- Attivo, non reclutante
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, Stati Uniti, 75390
- Attivo, non reclutante
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, Stati Uniti, 75063
- Terminato
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, Stati Uniti, 75063
- Terminato
- US Oncology Investigational Products Center
-
Irving, Texas, Stati Uniti, 75039
- Reclutamento
- NEXT Dallas
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- NEXT Oncology
-
San Antonio, Texas, Stati Uniti, 78240
- Attivo, non reclutante
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Attivo, non reclutante
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, Stati Uniti, 98362
- Attivo, non reclutante
- Olympic Medical Center
-
Poulsbo, Washington, Stati Uniti, 98370
- Attivo, non reclutante
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, Stati Uniti, 98109
- Attivo, non reclutante
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Stati Uniti, 98109
- Attivo, non reclutante
- University of Washington Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Altri nomi:
|
|
Sperimentale: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Altri nomi:
|
|
Sperimentale: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Altri nomi:
|
|
Sperimentale: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Altri nomi:
Oral continuous
Altri nomi:
|
|
Sperimentale: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Altri nomi:
Oral continuous
Altri nomi:
|
|
Sperimentale: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Altri nomi:
|
|
Sperimentale: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Altri nomi:
|
|
Sperimentale: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Altri nomi:
Oral continuous
Altri nomi:
|
|
Sperimentale: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Altri nomi:
Oral continuous
Altri nomi:
|
|
Sperimentale: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Altri nomi:
Oral continuous
Altri nomi:
Oral solution
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Lasso di tempo: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Lasso di tempo: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Lasso di tempo: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Lasso di tempo: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Lasso di tempo: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Lasso di tempo: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Lasso di tempo: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Lasso di tempo: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Lasso di tempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Lasso di tempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Lasso di tempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Lasso di tempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Lasso di tempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Lasso di tempo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Lasso di tempo: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Lasso di tempo: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Pfizer CT.gov Call Center, Pfizer
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- sicurezza
- farmacocinetica
- etichetta aperta
- efficacia
- mCRPC
- farmacodinamica
- FL
- ricaduto
- refrattario
- carcinoma polmonare a piccole cellule
- aumento della dose
- SCLC
- linfoma follicolare
- espansione della dose
- EZH2
- carcinoma prostatico resistente alla castrazione
- potenziatore dell'omologo zeste 2
- prostatecancer-study.com
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie per sede
- Neoplasie
- Attributi della malattia
- Malattie del sistema immunitario
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Ricorrenza
- Carcinoma polmonare a piccole cellule
- Linfoma, follicolare
- Composti eterociclici, 1-anello
- Composti eterociclici
- Azoli
- Triazoli
- Piperazines
- Itraconazolo
- Enzalutamide
- PF06821497
Altri numeri di identificazione dello studio
- C2321001
- 2023-509179-18-00 (Identificatore di registro: CTIS (EU))
- EZH2 (Altro identificatore: Alias Study Number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .